Trial Profile
Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms MITO16MANGO2b
- 23 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 23 Mar 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.
- 09 Mar 2021 Planned End Date changed from 1 Jul 2018 to 1 Dec 2022.